Breakthrough drug trial aims to halt rare eye disease progression
Disease control
Not yet recruiting
This study is testing whether the drug ALK-001 can safely slow down the progression of Stargardt disease, a rare genetic condition that causes vision loss. It will involve 230 participants aged 8 to 45 who have been diagnosed with the disease. Participants will be randomly assign…
Phase: PHASE3 • Sponsor: Alkeus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC